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Introduction
Antithyroid drugs are commonly used to control hy-
perthyroidism, especially when patients refuse other
therapies such as radioiodine and surgery. Despite their
acceptability, especially in Eastern countries, antithy-
roid drugs are associated with many complications.
Of the known complications, antithyroid drug-induced
agranulocytosis, although rare, is the most severe and
life-threatening. We retrospectively studied cases of
antithyroid drug-induced agranulocytosis over the past
10 years (1998–2008) in a Taiwanese medical center.
We searched for patients who had used antithyroid
drugs for the treatment of hyperthyroidism, had no
other disease, had taken no other drugs that could
have induced agranulocytosis, and had a neutrophil
count < 500/μL. A clinical evaluation was conducted,




Patient 1 was a 77-year-old woman with a history of
hyperthyroidism for 20 years. She had received pro-
pylthiouracil therapy (50 mg thrice daily) for 1 year,
which was switched to methimazole (5 mg thrice daily)
18 days before hospitalization. The patient had had 
a fever, headache and diarrhea since 10 days before
hospitalization. White blood cell count was 940/μL,
and the absolute neutrophil count was 60/μL. Granu-
locyte colony-stimulating factor and antibiotics were
provided. White blood cell count recovered to 7,870/
μL, and the absolute neutrophil count recovered to
3,856/μL on the 13th day. The symptoms also resolved.
Case 2
Patient 2 was a 53-year-old woman with Graves’ dis-
ease with hyperthyroidism diagnosed 2 months before
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hospitalization. The patient had started treatment with
methimazole (10 mg thrice daily) 46 days before hos-
pitalization. Sore throat, fever, diarrhea, and epigastric
pain developed 11 days before hospitalization. White
blood cell count was 450/μL, and the absolute neutro-
phil count was 20/μL. Granulocyte colony-stimulating
factor was provided with antibiotics. Blood and stool
cultures were performed, which yielded negative re-
sults. White blood cell count recovered to 5,810/μL
on the 7th day after the treatment began, and the
symptoms also improved. A subsequent thyroid scan
showed that the uptake of I-131 had increased. I-131
therapy, 5 mCi, was then provided.
Case 3
Patient 3 was a 43-year-old woman with a history of
Graves’ disease and hyperthyroidism for 2 years. The
patient had initially been treated with antithyroid drugs
for 3–4 months, but had stopped treatment because
of mild leukopenia. About 1 year before this hospital-
ization, hand tremors were noted. The patient took
propylthiouracil (50 mg twice daily) for 7 days. One
month before hospitalization, the same symptoms were
noted. Methimazole treatment (10 mg thrice daily)
began. Fever and sore throat were noted 2 days before
hospitalization. White blood cell count was 1,200/μL,
and the absolute neutrophil count was 252/μL. 
A blood culture was negative. Treatment with gran-
ulocyte colony-stimulating factor (75 μg/day) and
antibiotics began. The dosage was increased to 300μg/
day on the 4th day due to poor response. White blood
cell count recovered to 4,090/μL on the 10th day.
The patient’s fever subsided when the agranulocytosis
resolved. One month later, I-131 therapy, 6 mCi, was
provided.
Case 4
Patient 4 was a 62-year-old woman with hyperthyroid-
ism who had received propylthiouracil (100 mg thrice
daily) since 24 days before this hospitalization. Fever
and sore throat were noted 2 days before hospitaliza-
tion, and pus formation was noted when she visited
our ward. White blood cell count was 1,710/μL, and
the absolute neutrophil count was 169/μL. A throat
swab culture yielded Staphylococcus aureus. Blood and
urine cultures were negative. Propylthiouracil was dis-
continued, and antibiotic therapy was initiated. White
blood cell count recovered to 3,100/μL, and the ab-
solute neutrophil count recovered to 1,758/μL on
the 3rd day.
Discussion
Four cases were included in this analysis (Table 1).
Two cases had symptoms of agranulocytosis even after
therapy with propylthiouracil was switched to methi-
mazole. Fever and sore throat were the most common
Table 1. Clinical characteristics of antithyroid drug-induced agranulocytosis
Patient
1 2 3 4
Sex Female Female Female Female
Age (yr) 77 53 43 62
Duration of hyperthyroidism 20 yr 2 mo 2 yr 2 mo
Drug(s) used Propylthiouracil/ Methimazole Propylthiouracil/ Propylthiouracil
methimazole methimazole
Duration of drug use Propylthiouracil (1 yr)/ Methimazole (46 d) Propylthiouracil (7 d)/ Propylthiouracil 
methimazole (18 d) methimazole (28 d) (24 d)
Initial WBC count (cells/μL) 940 450 1,200 1,710
Initial ANC (cells/μL) 60 0 252 169
Symptoms Fever, headache, Fever, sore throat, Fever, sore throat Fever, sore throat
diarrhea diarrhea
GCSF duration (d) 11 7 11 Not used
GCSF dosage (μg) 75 for 5 d, 75 for 7 d 75 for 4 d, Not used
300 for 6 d 300 for 7 d
Recovery time (d) 13 7 10 3
WBC = white blood cell; ANC = absolute neutrophil count; GCSF = granulocyte colony-stimulating factor.
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symptoms, followed by diarrhea. The initial white
blood cell counts ranged from 450/μL to 1,710/μL.
Only 1 case had a positive result from throat swab
culture (S. aureus). Three of 4 cases received granu-
locyte colony-stimulating factor therapy. The time to
recovery ranged from 3 to 13 days. Mean recovery
time in patients with granulocyte colony-stimulating
factor therapy (Cases 1–3) was 10 days. Case 1, who
was older than 65 years of age, took a longer time to
recover than the other 3 patients, who were younger
than 65 years of age. All 4 patients recovered from
agranulocytosis.
Antithyroid drugs, especially thioamides—including
propylthiouracil, methimazole and carbimazole—have
adverse hematological effects, ranging from mild leu-
kopenia to agranulocytosis and aplastic anemia. Mild
leukopenia, defined as a total white blood cell count
< 4,000/μL, is noted in about 12% of adults and 25%
of children taking propylthiouracil.1 However, this
phenomenon is usually transient and does not usually
increase the risk of infection and herald the onset of
agranulocytosis. Thus, it is not necessary to stop treat-
ment with antithyroid drugs if mild leukopenia devel-
ops.2 Agranulocytosis, defined as a marked decrease
in the number of granulocytes, frequently < 500/μL,
is a rare complication. The incidence of antithyroid
drug-induced agranulocytosis is 0.55% with propyl-
thiouracil use and 0.31% with methimazole use.3 The
incidence of aplastic anemia caused by thioamides is
very rare.4 Only about 34 cases have been reported in
the past 50 years.5 However, of all the adverse reactions
to antithyroid drugs, agranulocytosis and neutropenia
account for 49% of mortality.6
Antithyroid drug-induced agranulocytosis occurs
most frequently in the first 3 months of treatment,
but it can occur after long-term treatment.7,8 High
doses of antithyroid drugs can increase the risk of
agranulocytosis, but this notion is debatable.8–10 Rou-
tine monitoring of white blood cell counts is recom-
mended in patients taking antithyroid drugs; however,
this practice is not foolproof because severe complica-
tions can occur suddenly and mild leukopenia does
not necessarily herald the onset of agranculocytosis.1,3
Educating patients about the prodromes of antithy-
roid drug-induced agranulocytosis (e.g. fever, sore
throat, and cervical lymphadenopathy) may be more
beneficial.4
Antithyroid drug-induced agranulocytosis is medi-
ated by a variety of mechanisms, including direct toxic
effects and immunological reactions. The direct toxic
effects affect both mature circulating neutrophils and
stem cells. The immunological reactions include the
following: immunoglobulin E-mediated hypersensitivity
reaction, drug-induced immunoglobulin G and M re-
sponses, and neutrophil-drug complex.11,12 Fever and
sore throat are common symptoms of antithyroid drug-
induced agranulocytosis. Patients with an absolute neu-
trophil count < 100/μL tend to have a greater risk of
infectious and fatal complications than do patients with
a neutrophil count > 100/μL. The mortality rate is
greater in patients aged ≥ 65 years than in those aged
< 65 years.6
Bone marrow examinations have revealed signs of
decreased generation of neutrophil granulocytes, in-
cluding the observation of impaired generation of
granulocyte precursor cells.13 In patients with antithy-
roid drug-associated aplastic anemia, bone marrow
examinations yielded hypocellularity.12 Patients with
granulocyte-to-erythrocyte count ratio (G:E) < 0.5 in
bone marrow took a significantly longer time to re-
cover from agranulocytosis after granulocyte colony-
stimulating factor therapy (mean, 9.8 days) than
patients with G:E ≥ 0.5 (mean, 2.2 days; p < 0.001).14
Treatment with granulocyte colony-stimulating
factor decreases the time of recovery from agranulo-
cytosis, the rate of complications from infection, and
the mortality rate, even in patients with asymptomatic
agranulocytosis.13 Mean recovery time in patients with
granulocyte colony-stimulating factor therapy is 6.8
days.14 After recovery from agranulocytosis, doctors
should be cautious about prescribing antithyroid drugs
again, even another type of thioamide, due to com-
mon cross-reactions among thioamides.1 Radioiodine
therapy or surgery may be better choices than the use
of another type of antithyroid drug. Our cases were
similar to previous ones in that there was good prog-
nosis after granulocyte colony-stimulating factor and
empirical antibiotic therapy, and the most common
symptoms were fever and sore throat. However, the
recovery time in our cases was slightly longer than in
previous cases (10 vs. 6.8 days).
In conclusion: (1) conducting a routine complete
blood cell count is beneficial in alerting caregivers to
the possibility of agranulocytosis; (2) educating patients
about the common symptoms of agranulocytosis may
contribute to an early diagnosis; (3) providing granu-
locyte colony-stimulating factor therapy to patients
results in a good prognosis; and (4) monitoring for
cross-reactions between drugs should be performed
to prevent further episodes of agranulocytosis.
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